DaShenLin Pharmaceutical Group (603233.SS) Earnings Analysis
DaShenLin Pharmaceutical Group (603233.SS) next reports earnings on 2026-08-25, consensus EPS 0.3371 CNY. Last quarter (2026-04-30) it beat with EPS 0.45 CNY vs 0.4494 CNY est (+0.1%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E 16.54.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 603233.SS next report earnings?
| Next earnings date | 2026-08-25 |
|---|---|
| Consensus EPS estimate | 0.3371 CNY |
| Revenue estimate | 7.28B |
603233.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 0.45 CNY | 0.4494 CNY | +0.1% | Beat |
| 2026-04-24 | 0.1377 CNY | 0.08148 CNY | +69% | Beat |
| 2025-10-30 | 0.2498 CNY | 0.1795 CNY | +39.2% | Beat |
| 2025-04-25 | 0.4 CNY | 0.31 CNY | +29% | Beat |
| 2025-03-31 | 0.4 CNY | n/a | n/a | n/a |
| 2024-08-30 | 0.23 CNY | 0.36 CNY | -36.1% | Miss |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
603233.SS valuation and analyst view
| Trailing P/E | 16.54 |
|---|---|
| Trailing EPS | 1.133 CNY |
| Price / book | 2.70 |
| Dividend yield | 4.44% |
| Market cap | 21.36B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is DaShenLin Pharmaceutical Group (603233.SS)'s next earnings date?
DaShenLin Pharmaceutical Group is next scheduled to report on 2026-08-25, with a consensus EPS estimate of 0.3371 CNY and revenue estimate of 7.28B.
Did 603233.SS beat earnings last quarter?
In its 2026-04-30 report, 603233.SS posted EPS of 0.45 CNY versus a 0.4494 CNY estimate — a beat of 0.1%.
What is 603233.SS's earnings track record?
Over the last 5 reported quarters with consensus data, 603233.SS beat estimates 4 times (80%).
What is 603233.SS's current P/E ratio and EPS?
603233.SS trades at a trailing P/E of 16.54 on trailing EPS of 1.132513872532096 CNY.
What do analysts rate 603233.SS?
603233.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.